research Selectively Targeting JAK1 or JAK3 Pathway Is Sufficient to Reverse Alopecia Areata
Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.
Search
for
Sort by
Research
30 / 1000+ resultsresearch Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata
Blocking JAK3 signaling can reverse hair loss from alopecia areata.
research Induction of T Cell Exhaustion by JAK1/3 Inhibition in the Treatment of Alopecia Areata
Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.
research Selective Janus Kinase 1 Inhibition Resolves Inflammation and Restores Hair Growth Offering a Viable Treatment Option for Alopecia Areata
Blocking Janus kinase 1 helps stop inflammation and regrow hair, making it a good treatment for hair loss from alopecia areata.
research The Efficacy and Safety of JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis of Prospective Studies
Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
research Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
research Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata
Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
research Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases
More precise, personalized therapies are needed for autoimmune diseases.
research Discovery Of A Novel And Highly Selective JAK3 Inhibitor As A Potent Hair Growth Promoter
MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.
research Real-World Experience and Long-Term Evaluation of Tofacitinib in Refractory Alopecia Areata: A Prospective, Open-Label, Single-Center Study in Asian Arab Population
Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
research Janus Kinase (JAK) Inhibitors for the Treatment of Skin and Hair Disorders: A Review of Literature
JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
research Drug News and Therapeutic News
JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
research Emerging Drugs for Alopecia Areata: JAK Inhibitors
JAK inhibitors may soon be a safe and effective treatment for alopecia areata.
research Comparative Efficacy and Safety of JAK Inhibitors in the Treatment of Moderate-to-Severe Alopecia Areata: A Systematic Review and Network Meta-Analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research JAK Inhibitors: New Players in the Field of Immune-Mediated Diseases Beyond Rheumatoid Arthritis
JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
research Janus Kinase Inhibitors in Dermatology: A Systematic Review
JAK inhibitors help with skin conditions but need more research on dosing and safety.
research JAK Inhibitors in Dermatology: The Promise of a New Drug Class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
research Rebound Effect Associated with JAK Inhibitor Use in the Treatment of Alopecia Areata
Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
research Targeting the Janus Kinase Family in Autoimmune Skin Diseases
Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
research Consensus on the Treatment of Alopecia Areata – Brazilian Society of Dermatology
Tailored treatments for alopecia areata are recommended based on severity and patient needs.
research Profile of Tofacitinib Citrate and Its Potential in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.
research Brazilian Experience of Treating Alopecia Universalis with Novel Antirheumatic Therapy Tofacitinib: A Case Series
Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
research Inflammatory Loops in the Epithelial-Immune Microenvironment of the Skin and Skin Appendages in Chronic Inflammatory Diseases
Chronic inflammatory skin diseases are caused by disrupted interactions between skin cells and immune cells.
research The JAK/STAT Signaling Pathway: From Bench to Clinic
The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
research MTOR Signaling in Hair Follicle and Hair Diseases: Recent Progress
The mTOR signaling pathway is crucial for hair health and targeting it may lead to new hair loss treatments.
research Enzymes
Enzymes are classified into six types and are essential for many biological processes, with only a few targeted by drugs.
research Enzymes
Enzymes play crucial roles in metabolism, health, and disease management.
research Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up
Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
research Advances in Understanding Hair Growth
Understanding glycans and enzymes that alter them is key to controlling hair growth.
research Unmet Medical Needs in Chronic, Non-Communicable Inflammatory Skin Diseases
There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.